City of Hope to Use Quest Diagnostics' Haystack MRD for Cancer Patient Management
City of Hope, a leading cancer research and treatment organization, is collaborating with Quest Diagnostics to evaluate the Haystack MRD test for managing patients with various cancers. The test, which uses circulating-tumor DNA (ctDNA) to detect minimal residual disease, will be implemented in clinical trials across 14 City of Hope sites in the U.S. The research aims to assess the test's ability to detect residual disease, monitor treatment response, and identify cancer recurrence earlier than traditional imaging methods. This collaboration is expected to involve approximately 500 patients and generate significant data on the test's efficacy in guiding treatment decisions for breast, colorectal, ovarian, and prostate cancers. 
